Gastric sleeve for PCOS is an increasingly discussed treatment pathway for women living with polycystic ovary syndrome and significant obesity. PCOS affects around 1 in 10 women in the UK and is closely linked to insulin resistance and weight gain, creating a cycle that can be difficult to break through lifestyle changes alone. Sleeve gastrectomy offers a surgical option that may substantially improve hormonal balance, menstrual regularity, and metabolic health. This article explains how PCOS and obesity interact, what gastric sleeve surgery involves on the NHS, who qualifies, the specific risks for women with PCOS, and the alternatives available.

How PCOS and obesity are linked

Insulin resistance in PCOS drives excess androgen production, and obesity amplifies this resistance, creating a cycle that increases risk of type 2 diabetes, cardiovascular disease, and infertility.

Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions affecting women of reproductive age in the UK, estimated to affect around 1 in 10 women (NHS). It is a heterogeneous condition, and diagnosis is typically based on the Rotterdam criteria: the presence of at least two of the following three features — irregular or absent periods, elevated androgen levels (or symptoms such as acne or hirsutism), and polycystic-appearing ovaries on ultrasound. Ultrasound is not required in all cases.

Whilst PCOS can affect women of any body weight, there is a well-established bidirectional relationship between PCOS and obesity that can significantly complicate both conditions.

Insulin resistance is common in PCOS and contributes to its hormonal features, but it is not present in all women with the condition. Where insulin resistance does occur, the pancreas produces excess insulin, which can stimulate the ovaries to produce more androgens (male hormones such as testosterone), worsening symptoms such as acne, hirsutism, and menstrual irregularity. Excess body weight can further amplify insulin resistance, creating a cycle that may be difficult to break through lifestyle measures alone.

Obesity in PCOS is associated with a higher risk of developing:

• Type 2 diabetes

• Cardiovascular disease

• Obstructive sleep apnoea

• Endometrial cancer (the absolute risk remains low, but chronic anovulation leads to prolonged unopposed oestrogen exposure, which increases relative risk over time)

• Infertility and pregnancy complications

When to seek GP advice: Women who have not had a period for more than three months, or who experience very heavy, irregular, intermenstrual, or postcoital bleeding, should contact their GP for assessment, including consideration of endometrial protection.

Even modest weight loss of 5–10% of body weight has been shown in clinical studies to improve menstrual regularity, reduce androgen levels, and restore ovulation in some women (NICE CKS: Polycystic ovary syndrome). This evidence underpins the rationale for considering bariatric interventions, including gastric sleeve surgery, as a potential treatment pathway for women with PCOS and significant obesity.

What gastric sleeve surgery involves on the NHS

Sleeve gastrectomy removes 75–80% of the stomach laparoscopically, reducing ghrelin levels and stomach capacity; NHS patients access it via a Tier 3 specialist weight management pathway with lifelong nutritional follow-up.

Sleeve gastrectomy, commonly referred to as gastric sleeve surgery, is a form of bariatric (weight loss) surgery in which approximately 75–80% of the stomach is surgically removed, leaving a narrow, tube-shaped 'sleeve'. This procedure is performed laparoscopically (keyhole surgery) under general anaesthetic and typically requires a hospital stay of two to three days.

Unlike gastric bypass, the gastric sleeve does not reroute the intestines, making it a primarily restrictive procedure. Whilst the risk of nutritional malabsorption is lower than with bypass surgery, nutritional deficiencies remain common and lifelong vitamin and mineral supplementation is essential for all patients.

The mechanism by which gastric sleeve surgery promotes weight loss is twofold. First, the dramatically reduced stomach capacity limits the volume of food that can be consumed at any one time. Second, the removal of the gastric fundus substantially reduces circulating levels of ghrelin — the hormone responsible for stimulating hunger — meaning patients often experience a marked reduction in appetite beyond what would be expected from restriction alone.

On the NHS, gastric sleeve surgery is commissioned as part of a structured bariatric pathway. Patients are typically referred to an NHS Tier 3 specialist weight management service before being considered for surgery. This multidisciplinary team (MDT) includes:

• A bariatric surgeon

• A specialist dietitian

• A clinical psychologist

• An endocrinologist or physician with expertise in obesity medicine

Pre-operative preparation usually involves dietary optimisation, psychological assessment, and in some cases a very low calorie diet (VLCD) to reduce liver size and improve surgical safety.

Post-operative nutritional care is lifelong. In line with British Obesity and Metabolic Surgery Society (BOMSS) guidance, patients require a complete multivitamin and mineral supplement, calcium with vitamin D, iron, and vitamin B12 as a minimum. Thiamine (vitamin B1) supplementation should be considered, particularly if prolonged vomiting occurs. Biochemical monitoring is recommended at 3, 6, and 12 months post-operatively, then annually, and should include full blood count, ferritin, folate, vitamin B12, vitamin D, calcium, and parathyroid hormone (PTH), with additional tests as clinically indicated per BOMSS guidance.

Patients should also be aware that gastric sleeve surgery can worsen or cause new gastro-oesophageal reflux disease (GORD), and some may require long-term acid suppression or, in rare cases, conversion to a different procedure. Rapid weight loss also increases the risk of gallstone formation; some centres prescribe ursodeoxycholic acid prophylactically in the post-operative period.

Who qualifies for bariatric surgery with PCOS in the UK

PCOS alone does not qualify a patient for NHS bariatric surgery; women must also meet NICE BMI thresholds — typically 40 kg/m² or above, or 35–39.9 kg/m² with a significant comorbidity.

Access to bariatric surgery on the NHS is governed by NICE guidance. PCOS itself is not a standalone criterion for bariatric surgery, but women with PCOS who also meet the standard eligibility thresholds may be referred through the appropriate pathway.

According to NICE guidance (CG189: Obesity — identification, assessment and management, and NG28: Type 2 diabetes in adults), adults are generally considered for bariatric surgery if they meet one of the following criteria:

• A BMI of 40 kg/m² or above

• A BMI of 35–39.9 kg/m² with a significant obesity-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• A BMI of 30–34.9 kg/m² with recent-onset type 2 diabetes — this group may be considered for expedited referral (NICE NG28)

• People of Asian family origin may be assessed at lower BMI thresholds in the context of type 2 diabetes, reflecting higher metabolic risk at lower body weight (NICE NG28)

For women with PCOS, the presence of insulin resistance, type 2 diabetes, or metabolic syndrome may strengthen the clinical case for surgical referral. Referral is typically made by a GP to an NHS Tier 3 specialist weight management service, which assesses suitability for surgery. Patients are generally expected to have engaged with non-surgical weight management interventions first, demonstrating commitment to lifestyle change.

It is important to note that NHS commissioning of bariatric surgery varies by Integrated Care Board (ICB), and waiting times can be lengthy. Patients should check their local ICB commissioning policy for specific criteria. Some women with PCOS choose to pursue surgery privately, though this does not negate the need for thorough pre-operative assessment and long-term follow-up.

Women who are planning a pregnancy should discuss timing carefully with their clinical team, as surgery is generally not recommended immediately before conception (see the section on risks and considerations below).

Risks and considerations specific to PCOS patients

Key PCOS-specific risks include rapid return of ovulation requiring immediate contraception, increased iron deficiency if periods resume, and persistent hormonal imbalance requiring ongoing specialist management.

Gastric sleeve surgery carries the same general surgical risks as any major abdominal procedure, including bleeding, infection, venous thromboembolism, and anaesthetic complications. Procedure-specific risks include staple line leaks, worsening of gastro-oesophageal reflux disease (GORD), and nutritional deficiencies. There are several considerations that are particularly relevant to women with PCOS.

Urgent red flags after surgery: Patients and their carers should seek immediate medical attention if they experience severe abdominal, chest, or shoulder-tip pain; a rapid heart rate; high temperature; or persistent vomiting or retching in the post-operative period. These may indicate serious complications such as a staple line leak, pulmonary embolism, or obstruction.

Not sure if this is normal? Chat with one of our pharmacists →

Fertility and contraception require careful attention. Weight loss following bariatric surgery can rapidly restore ovulation in women who were previously anovulatory due to PCOS. Whilst this is broadly positive for long-term fertility, it also means that women who do not wish to conceive must use reliable contraception post-operatively.

After a primarily restrictive procedure such as gastric sleeve, combined hormonal contraception (CHC) may be used, but women should be counselled that vomiting or diarrhoea can reduce absorption. Long-acting reversible contraception (LARC) — such as the subdermal implant or an intrauterine device (IUD/IUS) — is recommended as first-line after bariatric surgery, as absorption is not affected (FSRH guidance: Contraception after bariatric surgery).

In line with FSRH and NICE advice, pregnancy should ideally be avoided for 12–18 months after bariatric surgery, and some guidance extends this to up to 24 months, to allow nutritional stabilisation. Women planning a pregnancy after bariatric surgery should take folic acid 5 mg daily preconceptually (recommended for women with a BMI ≥30 or following bariatric surgery) and coordinate care with both their bariatric and maternity teams.

Nutritional deficiencies are a significant concern for women with PCOS post-surgery, particularly those of reproductive age. Iron deficiency is common in women who menstruate, and if periods resume or become heavier following surgery, this risk increases. Vitamin D deficiency, already prevalent in PCOS, may worsen without adequate supplementation. If prolonged vomiting occurs, thiamine (vitamin B1) deficiency is a risk and supplementation should be considered promptly. Biochemical monitoring should follow BOMSS guidance (see the surgery section above).

Women should also be aware that whilst gastric sleeve surgery can significantly improve PCOS symptoms, it does not constitute a cure. Hormonal imbalances may persist in some individuals, and ongoing management with a gynaecologist or endocrinologist may still be required.

Other treatment options alongside or instead of surgery

First-line management for overweight women with PCOS is structured lifestyle intervention; pharmacological options include metformin, orlistat, and GLP-1 receptor agonists such as semaglutide, used alongside or instead of surgery.

For many women with PCOS, bariatric surgery will not be appropriate or accessible, and a range of evidence-based alternatives exist. The first-line approach recommended by NICE for overweight women with PCOS remains structured lifestyle intervention, combining dietary modification, increased physical activity, and behavioural support. Even modest weight loss can meaningfully improve hormonal profiles, menstrual regularity, and metabolic health (NICE CKS: Polycystic ovary syndrome).

Pharmacological options may be used alongside lifestyle measures:

• Metformin is used off-label in PCOS (it is not licensed specifically for this indication in the UK) to improve insulin sensitivity, reduce androgen levels, and support weight management. It is particularly beneficial in women with impaired glucose tolerance or type 2 diabetes. Common side effects include nausea, diarrhoea, and abdominal discomfort, which are often reduced by taking it with food or using a modified-release formulation. Renal function should be checked before starting and monitored during treatment (BNF).

• Orlistat (Xenical) is a licensed weight loss medication that inhibits intestinal lipase, reducing dietary fat absorption by approximately 30%. In the UK, it is indicated for adults with a BMI ≥30 kg/m², or ≥28 kg/m² with weight-related comorbidities. Common side effects include oily stools, faecal urgency, and flatulence, which are reduced by following a low-fat diet. As orlistat reduces absorption of fat-soluble vitamins (A, D, E, and K), supplementation should be taken at a different time of day (MHRA/EMC SmPC: Orlistat).

• GLP-1 receptor agonists such as semaglutide (Wegovy) represent a newer class of weight management medication. In the UK, semaglutide 2.4 mg is approved for use in specialist weight management services for adults with a BMI ≥35 kg/m² (or ≥30 kg/m² in certain higher-risk groups) with at least one weight-related comorbidity (NICE TA875). Early evidence suggests GLP-1 receptor agonists may also improve insulin resistance and androgen levels in PCOS, but they are not licensed for PCOS specifically. Common side effects include nausea, vomiting, and diarrhoea. Semaglutide must not be used during pregnancy and effective contraception is required during treatment; women should stop treatment at least two months before attempting to conceive (MHRA/EMC SmPC: Wegovy).

• Spironolactone is sometimes used off-label as an anti-androgen to manage hirsutism or acne in PCOS. It is teratogenic and must not be used during pregnancy. Women of childbearing potential must use reliable contraception throughout treatment (BNF).

For women whose primary concern is menstrual irregularity or hyperandrogenism rather than weight, hormonal treatments such as the combined oral contraceptive pill may be appropriate. Women experiencing infertility related to anovulation may be referred to a reproductive medicine specialist for ovulation induction.

Reporting side effects: Patients are encouraged to report any suspected side effects from medicines to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Ultimately, the management of PCOS is highly individualised. Women are encouraged to discuss their full range of options with their GP or a specialist, taking into account their symptoms, reproductive goals, metabolic health, and personal preferences. If you are concerned about your weight or PCOS symptoms, contacting your GP is the appropriate first step.

Frequently Asked Questions